NIMOTOP

This brand name is authorized in Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Germany, Hong Kong SAR China, Ireland, Malta, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug NIMOTOP contains one active pharmaceutical ingredient (API):

1	Nimodipine UNII 57WA9QZ5WH - NIMODIPINE
	Nimodipine is a dihydropyridine calcium channel blocker with particular cerebrovascular effect. Nimodipine increases cerebral perfusion, particularly in poorly perfused areas, by arterial dilatation, an effect which is proportionately greater in smaller than in larger vessels.
	Read more about Nimodipine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NIMOTOP Film-coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
NIMOTOP 0.02% Solution for infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C08CA06	Nimodipine	C Cardiovascular system → C08 Calcium channel blockers → C08C Selective calcium channel blockers with mainly vascular effects → C08CA Dihydropyridine derivatives
Discover more medicines within C08CA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02325926
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00165333, 01549969, 03673254, 06151384
EE	Ravimiamet	1006254, 1006287, 1510221
ES	Centro de información online de medicamentos de la AEMPS	58075
FI	Lääkealan turvallisuus- ja kehittämiskeskus	086553, 086587
FR	Base de données publique des médicaments	61339638, 65726536
GB	Medicines & Healthcare Products Regulatory Agency	373063, 38794
HK	Department of Health Drug Office	28973, 28974
HR	Agencija za lijekove i medicinske proizvode	HR-H-331612666, HR-H-637102533
IE	Health Products Regulatory Authority	36517
MT	Medicines Authority	AA639/02402, MA639/02401
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	122M88, 123M88
NL	Z-Index G-Standaard	13484494
NL	Z-Index G-Standaard, PRK	27588, 27596
NZ	Medicines and Medical Devices Safety Authority	6608, 6609
PL	Rejestru Produktów Leczniczych	100034556, 100047470, 100247447, 100264180, 100293252, 100293648, 100323869, 100332259, 100363490, 100396006, 100421247, 100423677, 100425311, 100465827
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63887001, W63887002, W63888001, W63888002, W63888003, W63888004
SG	Health Sciences Authority	06931P, 09111P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699546010387, 8699546750399
ZA	Health Products Regulatory Authority	T/7.1/229, T/7.1/230